Filgotinib

Drug Profile

Filgotinib

Alternative Names: G-146034; GLPG-0634; GS-6034

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Galapagos NV
  • Developer Galapagos NV; Gilead Sciences
  • Class 2 ring heterocyclic compounds; Amides; Anti-inflammatories; Antirheumatics; Cyclopropanes; Pyridines; Small molecules; Thiamorpholines; Triazoles
  • Mechanism of Action Janus kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Crohn's disease; Rheumatoid arthritis; Ulcerative colitis
  • Phase II Ankylosing spondylitis; Cutaneous lupus erythematosus; Lupus nephritis; Psoriatic arthritis; Sjogren's syndrome; Uveitis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Crohn's-disease(In the elderly, In volunteers, In adults) in Germany (PO, Tablet)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Rheumatoid-arthritis(In the elderly, In volunteers) in Belgium (PO, Capsule)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Rheumatoid-arthritis(In volunteers) in Belgium (PO, Liquid)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top